Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3427 clinical trials
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

The primary objective of the study is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine is given concomitantly with routine pediatric …

tetanus
immunization schedule
influenzae
haemophilus
antibiotic therapy
  • 0 views
  • 19 Feb, 2024
  • 29 locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

The primary objective of the study is to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine is given concomitantly with routine pediatric …

tetanus
immunization schedule
influenzae
haemophilus
antibiotic therapy
  • 0 views
  • 19 Feb, 2024
  • 29 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of …

  • 0 views
  • 19 Feb, 2024
  • 31 locations
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

liver transplant
neutrophil count
nivolumab
hypothyroidism
carcinoma
  • 0 views
  • 19 Feb, 2024
Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in …

hypoalbuminemia
hepatic decompensation
gastric varices
thrombocytopenia
early diagnosis
  • 0 views
  • 19 Feb, 2024
Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients

To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV negative heart recipients who are currently listed.

hepatitis c
heart transplantation
  • 0 views
  • 19 Feb, 2024
HCV Reinfection After DAA Therapy in PWID in Belgium

The primary aim of this study is to calculate the incidence of HCV reinfection after successful DAA treatment among people who have recently injected drugs. The secondary aim is to identify factors associated with reinfection in this population. Individuals with active injecting drug abuse with a chronic HCV infection who …

hepatitis
  • 0 views
  • 19 Feb, 2024
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and excess fat in the liver. Surgical excision of these liver lesions is the reference treatment but it cannot always be realised.

metastasis
liver cancer
colorectal cancer
liver diseases
skin cancer
  • 0 views
  • 19 Feb, 2024
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

moderate hepatic impairment
systolic blood pressure
follicle stimulating hormone
bilateral salpingectomy
diastolic blood pressure
  • 0 views
  • 19 Feb, 2024
Longitudinal Immune-phenotyping of HCC Following MK-3475

The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …

metastasis
neutrophil count
serum bilirubin level
immunomodulator
aptt
  • 0 views
  • 19 Feb, 2024